Pharmaceutical giant AstraZeneca’s agreement to sell much of its antibiotics business won’t impact operations at MedImmune, its Gaithersburg-based research and development arm, officials confirmed Wednesday.
{iframe}http://www.bizjournals.com/washington/news/2016/08/25/medimmune-wont-be-impacted-by-astrazeneca-sale-of.html{/iframe}